Drugs / 68Ga-NY104
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05638256 | Oct 2022 → Oct 2023 | renal cell carcinoma | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
| Phase 0 | NCT05728515 | Dec 2021 → Mar 2022 | clear cell renal carcinoma | Peking Union Medical College Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NY104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05638256 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-labeled NY104 PET Imaging in Patients” NCT05638256 ↗ |
| Route | Intravenous | “Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY104” NCT05638256 ↗ |
| Target | CA9 | “68Ga-NY104 can efficiently and specifically bind to CAIX.” PMID 37246998 ↗ May 2023 |